Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol

References

• Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, . Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007;92: 952–9.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–49.
   PubMed Web of Science ®Google Scholar
• Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood. 1995;86:3493–9.
   PubMed Web of Science ®Google Scholar
• Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103:3065–72.
   PubMed Web of Science ®Google Scholar
• Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011;137:305–10.
   PubMed Web of Science ®Google Scholar
• Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:181–7.
   PubMed Web of Science ®Google Scholar
• Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009;27:130–9.
   PubMed Web of Science ®Google Scholar
• Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, . Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1679–87.
   PubMed Web of Science ®Google Scholar
• Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs. 2009;69: 1483–512.
   PubMed Web of Science ®Google Scholar
• Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, . Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med. 2010;8:129.
   PubMed Web of Science ®Google Scholar
• McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, . Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 1998;38: 938–43.
   PubMedGoogle Scholar
• Lecoeur H, de Oliveira-Pinto LM, Gougeon ML. Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J Immunol Methods. 2002;265: 81–96.
   Google Scholar
• Cholujova D, Jakubikova J, Kubes M, Arendacka B, Sapak M, Ihnatko R, . Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays. Immunobiology. 2008;213:629–40.
   PubMed Web of Science ®Google Scholar
• De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56dim CD16+ NK cells as rapid producers of abundant IFN-γ on activation. Proc Natl Acad Sci USA. 2011;108: 728–32.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, . Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood. 2001;97:3146–51.
   PubMed Web of Science ®Google Scholar
• Rutella S, Bonanno G, Marone M, De Ritis D, Mariotti A, Voso MT, . Identification of a novel subpopulation of human cord blood CD34– CD133– CD7–CD45+ lineage– cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J Immunol. 2003;171:2977–88.
   Google Scholar
• Bonanno G, Mariotti A, Procoli A, Corallo M, Scambia G, Pierelli L, . Interleukin-21 induces the differentiation of human umbilical cord blood CD34– lineage– cells into pseudomature lytic NK cells. BMC Immunol. 2009; 10:46.
   Google Scholar
• Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, . The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy. 2012;14:91–103.
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc Natl Acad Sci USA. 1999;96:6879–84.
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734–8.
   PubMed Web of Science ®Google Scholar
• Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, . Dual-functional capability of CD3+ CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 2011;118: 3301–10.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, . Cancer statistics, 2008. CA Cancer J Clin. 2008;58: 71–96.
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, . Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53.
   PubMed Web of Science ®Google Scholar